Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 1/20 | 0.41 |
| ▸ | CNR2 | P34972 | 14/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | PRKCG | P05129 | 2/20 | 0.34 |
| ▸ | PRKCB | P05771 | 2/20 | 0.34 |
| ▸ | PRKCA | P17252 | 2/20 | 0.34 |
| ▸ | PRKACA | P17612 | 2/20 | 0.34 |
| ▸ | PRKCH | P24723 | 2/20 | 0.34 |
| ▸ | PRKCE | Q02156 | 2/20 | 0.34 |
| ▸ | PRKCD | Q05655 | 2/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | PRKACG | P22612 | 1/20 | 0.34 |
| ▸ | PRKACB | P22694 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4380363 | 1.00 | CNR1 (0.41) | CNR1CNR2TSHRPRKCGPRKCB | |
| SCHEMBL4379580 | 0.83 | CNR1 (0.51) | CNR1CNR2TSHRNPC1RAB9A | |
| SCHEMBL4375139 | 0.83 | CNR2 (0.38) | CNR1CNR2TSHR | |
| SCHEMBL4374057 | 0.81 | TSHR (0.37) | CNR1CNR2TSHRTDP1L3MBTL1 | |
| SCHEMBL4369702 | 0.80 | CNR1 (0.53) | CNR1CNR2TSHRNPC1RAB9A | |
| SCHEMBL5615341 | 0.78 | CNR1 (0.66) | CNR1CNR2TSHRNPC1RAB9A | |
| SCHEMBL4371133 | 0.77 | CNR1 (0.44) | CNR1CNR2TSHRNPC1RAB9A | |
| SCHEMBL4371132 | 0.77 | CNR1 (0.44) | CNR1CNR2TSHRNPC1RAB9A | |
| SCHEMBL4371543 | 0.73 | CNR1 (0.53) | CNR1CNR2TSHRNPC1RAB9A | |
| SCHEMBL4376045 | 0.72 | TSHR (0.42) | CNR1CNR2TSHRTDP1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7563910-B2 | Heterocyclic cannabinoid receptor antagonists | HOFFMANN-LA ROCHE INC. (US) | 2009-07-21 | — | — | US | claimed |
| EP-1749002-B1 | PYRROLE OR IMIDAZOLE AMIDES FOR TREATING OBESITY | HOFFMANN LA ROCHE (CH) | 2009-05-27 | — | — | EP | claimed |
| EP-1749002-A1 | PYRROLE OR IMIDAZOLE AMIDES FOR TREATING OBESITY | F.HOFFMANN-LA ROCHE AG (CH) | 2007-02-07 | — | — | EP | claimed |
| WO-2005108393-A1 | PYRROLE OR IMIDAZOLE AMIDES FOR TREATING OBESITY | F. HOFFMANN-LA ROCHE AG (CH) | 2005-11-17 | — | — | WO | claimed |
| US-20050250769-A1 | Heterocyclic cannabinoid receptor antagonists | F. HOFFMANN-LA ROCHE AG (CH) | 2005-11-10 | — | — | US | claimed |
| US-7563910-B2 | Heterocyclic cannabinoid receptor antagonists | HOFFMANN-LA ROCHE INC. (US) | 2009-07-21 | — | — | US | disclosed |
| EP-1749002-B1 | PYRROLE OR IMIDAZOLE AMIDES FOR TREATING OBESITY | HOFFMANN LA ROCHE (CH) | 2009-05-27 | — | — | EP | disclosed |
| EP-1749002-A1 | PYRROLE OR IMIDAZOLE AMIDES FOR TREATING OBESITY | F.HOFFMANN-LA ROCHE AG (CH) | 2007-02-07 | — | — | EP | disclosed |
| WO-2005108393-A1 | PYRROLE OR IMIDAZOLE AMIDES FOR TREATING OBESITY | F. HOFFMANN-LA ROCHE AG (CH) | 2005-11-17 | — | — | WO | disclosed |
| US-20050250769-A1 | Heterocyclic cannabinoid receptor antagonists | F. HOFFMANN-LA ROCHE AG (CH) | 2005-11-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050250769-A1 | Heterocyclic cannabinoid receptor antagonists | CNR1, CNR2, GPR18 | CNR1 1/4885CNR2 2/4885TSHR 497/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.